Opinion|Videos|November 27, 2024
Patient Selection and Personalized Treatment Strategies
Key Takeaways
- Transitioning from IV to oral medications requires careful management of adherence, side effects, and therapeutic efficacy to ensure optimal patient outcomes.
- Patient-specific factors, such as comorbidities and drug interactions, are critical in optimizing treatment during the transition from IV to oral medications.
An overview of challenges in transitioning from IV to oral medications and guidance on identifying NSCLC patient populations most likely to benefit from HER2-directed therapies through informed patient selection strategies.
Episodes in this series
Video content above is prompted by the following:
- What challenges may exist when transitioning from IV to oral medications?
- Which NSCLC patient populations are most likely to benefit from HER2-directed therapies and how should clinicians approach patient selection?
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.
Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.
“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.
Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5